SINGLE-APPLICATION TERBINAFINE HYDROCHLORIDE (1%) TOPICAL LIQUID SOLUTION VERSUS A SINGLE-APPLICATION BUTENAFINE HYDROCHLORIDE (1%) TOPICAL LIQUID SOLUTION FOR THE TREATMENT OF TINEA PEDIS
SINGLE-APPLICATION TERBINAFINE HYDROCHLORIDE (1%) TOPICAL LIQUID SOLUTION VERSUS A SINGLE-APPLICATION BUTENAFINE HYDROCHLORIDE (1%) TOPICAL LIQUID SOLUTION FOR THE TREATMENT OF TINEA PEDIS
Tinea pedis or athlete's foot is the most common fungal infection worldwide, caused by
 infection of the feet with dermatophytes such as Trichophyton rubrum, Trichophyton
 interdigitale (formerly Trichophyton mentagrophytes), and Epidermophyton floccosum. Diagnosis
 of tinea pedia involves clinical symptoms as well as microscopic examination. Topical
 therapies are usually applied once or twice daily for as long as 4 weeks, posing a challenge
 to compliance. The current study aims to test a formulation of the single-dose 1% terbinafine
 hydrochloride, as well as a single-dose 1% butenafine hydrochloride, versus a vehicle control
 in adult Filipino patients with athlete's foot. This study will benefit the Filipino
 community by helping us determine which anti-fungal cream is most effective for athlete's
 foot.
Inclusion Criteria:

 -  Male or nonpregnant females aged 18-60 years old.

 -  Clinical diagnosis of tinea pedis (total sign/symptom score >2), lesions between the
 toes, with possible extension to the lateral surfaces and soles of the feet confirmed
 by a positive microscopy prior to dosing.

 -  Willing to sign the informed consent.

 Exclusion Criteria:

 -  Females who are pregnant (confirmed by a pregnancy test), suspect themselves to be
 pregnant (even if pregnancy test is negative), breast-feeding, or planning a
 pregnancy.

 -  Signs of systemic or other superficial fungal disease (e.g.onychomycosis), clinically
 relevant abnormal findings upon physical examination of the foot or previous treatment
 with a disallowed medication (such as corticosteroids).

 -  Presence of non-healing wounds and/or bacterial infection on the feet.

 -  Secondary bacterial infection due to tinea pedis

 -  Presence of pigmentation, extensive scarring, or pigmented lesions in the treatment
 areas, which could interfere with the rating of efficacy parameters.

 -  History of hypersensitivity to any component of the test products.

 -  Current imuunosuppression. Specifically, these include ￼patients with co-morbidities
 such as diabetes, HIV, chronic diseases requiring maintenance medications, acute
 febrile/infectious illnesses (i.e. Dengue, pneumonia, etc)

 -  Use within 3 months prior to baseline of: 1.) chemotherapy, or 2.) radiation therapy